21 October 2021>: Articles
Treatment of Severe Immune Thrombocytopenic Purpura Associated with COVID-19
Challenging differential diagnosis, Unusual or unexpected effect of treatment, Educational Purpose (only if useful for a systematic review or synthesis), Rare coexistence of disease or pathology
Nayab Ahmed A* , Abdullah Asreb E , Rosemary Chofor E , Achenef Melese ADOI: 10.12659/AJCR.932557
Am J Case Rep 2021; 22:e932557
Table 1. Lab results on day of presentation.
Reference range & units | Day 1 of hospital admission | |
---|---|---|
WBC | 4.8–10.8×10³/uL | 10.1 |
RBC | 4.2–5.4 M/uL | 4.23 |
Hemoglobin | 12–16 GM/dL | 11.6 |
Hematocrit | 37–47% | 34.6 |
MCV | 81–99 fL | 81.8 |
MCH | 27–31 PG | 27.4 |
MCHC | 33–37% | 33.5 |
Platelets | 130–400×10³/uL | 0 |
Immature platelet fraction | 1.1–7.1% | 34.1 |
Protime | 9.4–12.5 s | 11.8 |
INR | 0.85–1.13 | 1.04 |
aPTT | 25.1–36.5 s | 27.2 |